Summary of Enovis Conference Call Company Overview - Enovis is positioned as a challenger brand in the orthopedic space, competing against the Big Four companies in the industry [2][3] - The company has a balanced portfolio with 50% of its business in the U.S. and 50% internationally, and it covers the entire patient continuum from prevention to recovery [3][4] Key Differentiators - Enovis emphasizes its innovative portfolio and agility in decision-making, which allows for close customer relationships and influence on product development [3][4] - The company aims to enhance commercial execution, operational excellence, and financial discipline to drive cash flow generation and reduce debt [5][10] Capital Allocation Strategy - Enovis has focused on integrating the Lima acquisition, which has performed better than expected, and is now prioritizing organic growth and debt reduction before pursuing further M&A [10][11] - The company is exploring various acquisition opportunities, including channel acquisitions and geographic expansions, but remains focused on the orthopedic sector [12][14] Product Pipeline and Innovations - The Arvis product is expected to be a significant growth driver, particularly in knee and shoulder segments, with a flexible customer-centric model for adoption [19][20] - Recent product launches, such as the augmented glenoid and hip systems, are performing well and are expected to capture a larger market share [26][27] Market Dynamics - The orthopedic market is experiencing growth, particularly in international markets, with a strong demand for shoulder procedures [29][30] - Enovis is leveraging its strong position in shoulder to expand its presence in hips and knees, although it currently holds low market shares in these areas [30][31] Pricing and Competitive Landscape - The company has been able to maintain competitive pricing in the PNR market, with slight price increases to offset inflation [31][32] - Enovis is focused on innovation in implant design to attract key opinion leaders and drive market share [32][34] Financial Performance and Projections - Enovis generated approximately $30 million in cash with a 70% free cash flow conversion in Q3, with expectations to improve cash flow generation moving forward [54][55] - The company anticipates EBITDA margin expansion driven by synergies from the Lima acquisition and a favorable business mix [57][58] Strategic Focus Areas - Enovis aims to maintain a balanced portfolio between recon and PNR, with a focus on solid growth in both areas to support cash generation for higher-growth segments [62][64] - The company sees opportunities in sports medicine and plans to explore this area further [65][66] Personalization and Innovation - Enovis is investing in personalized implant solutions, leveraging AI for process improvements, and aims to enhance its competitive advantage in this area [75][76] Investor Insights - There is a focus on improving cash generation and reducing leverage, with a target to bring the leverage ratio below three [78][79] - The company believes that as cash flow improves and debt is reduced, the market valuation will better reflect its potential [78]

Financial Data and Key Metrics Changes - The company reported first quarter sales of $559 million, an increase of 8% year-over-year and 10% on a constant currency basis [12][14] - Adjusted EBITDA margins improved by 160 basis points, reaching 17.7%, with adjusted earnings per share increasing by 62% to $0.81 [14][15] - Adjusted gross margins rose to 61.7%, an increase of 300 basis points year-over-year, driven by favorable segment and product mix [13][14] Business Line Data and Key Metrics Changes - The recon business experienced a comparable growth of 13%, with U.S. recon growing by 11%, including 12% growth in U.S. extremities and 10% growth in hips and knees [7][13] - The PNR segment achieved 8% comparable growth, with adjusted EBITDA margins improving by 50 basis points year-over-year [10][14] - The company anticipates high single-digit growth in recon and low single-digit growth in PNR for the year [15] Market Data and Key Metrics Changes - Internationally, the company grew by 14%, indicating strong performance in resilient markets [9] - The U.S. market showed a healthy start, with expectations for at least normal growth throughout the year [30][36] - The company noted a slight downward trend in the recon price environment, although new products are helping to offset this [88] Company Strategy and Development Direction - The company is focused on mitigating tariff impacts and enhancing supply chain resilience, with plans to transition at least 50% of tariff exposure by mid-2026 [19][66] - New product launches are expected to drive growth, with several key innovations scheduled for release throughout the year [9][59] - The management emphasized the importance of maintaining operational momentum and strategic goals despite external challenges [20][77] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the current economic environment, citing the resilience of the markets served [73][74] - The company remains committed to achieving annual margin expansion goals, despite potential delays due to tariffs [76][78] - Management highlighted a strong foundation and operational momentum, indicating optimism for continued growth [12][20] Other Important Information - The company is transitioning leadership, with Damian McDonald set to take over as CEO [102] - The company expects to maintain positive free cash flow in 2025, despite challenges from tariffs [15][49] Q&A Session Summary Question: What mitigating actions are most significant for long-term supply availability? - Management indicated that moving sourcing out of China is the most significant opportunity to mitigate tariff exposure [24] Question: How is the ARG launch performing and what are the market trends? - The ARG launch is progressing well, contributing positively to extremities growth, with a healthy start to the year overall [28][30] Question: How does U.S. performance compare across segments? - U.S. bracing performed strongly, while recon met expectations, with a good start to the year overall [36][39] Question: What is the outlook for gross margins? - Management noted that gross margin improvements are sustainable, driven by positive business mix and new product contributions [40][41] Question: How is the company addressing cash flow and CapEx? - The company expects to see improvements in free cash flow throughout the year, with elevated CapEx levels due to growth investments [62][66] Question: What is the pricing environment like? - The pricing environment remains flat in PNR, with a slight downward trend in recon prices, but new products are helping to mitigate impacts [88] Question: How durable is the international growth? - International growth is strong, with effective cross-selling strategies contributing to above-market performance [90][92]

Financial Data and Key Metrics Changes - The company reported first quarter sales of $559 million, an increase of 8% year-over-year and 10% on a constant currency basis [11][12] - Adjusted EBITDA grew 19%, delivering a margin of 17.7%, up 160 basis points compared to the same quarter last year [13] - Adjusted earnings per share reached $0.81, a 62% increase from the prior year [14] Business Line Data and Key Metrics Changes - The recon business achieved comparable growth of 13%, with U.S. recon growing 11%, including 12% growth in U.S. extremities and 10% growth in hips and knees [6][7][12] - The PNR segment reported 8% comparable growth, with adjusted EBITDA margins improving by 50 basis points year-over-year [9][12] Market Data and Key Metrics Changes - International growth in the recon business was 14%, indicating strong performance in resilient markets [8] - The U.S. market showed a healthy start, with bracing growing at 10%, while recon growth was in line with expectations [34][35] Company Strategy and Development Direction - The company is focused on new product innovations and has a clear line of sight to a multiyear cadence of meaningful new product introductions [5][8] - The management emphasized the importance of mitigating tariff impacts and optimizing supply chains to maintain growth momentum [16][18] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying fundamentals of the business, anticipating solid momentum into the second quarter [19] - The company remains committed to driving profitable growth and margin expansion despite potential headwinds from tariffs [75] Other Important Information - The company is increasing its revenue guidance for 2025 by $30 million, now expecting revenues between $2.22 billion and $2.25 billion [15] - The management is monitoring the tariff situation closely and has plans to mitigate the impact [18] Q&A Session Summary Question: What mitigating actions have the most significant potential for durable supply availability? - Management highlighted the importance of quickly moving sourcing out of China to reduce tariff exposure [23] Question: How is the ARG launch performing and what are the general market trends? - The ARG launch is progressing well, contributing positively to extremities growth, with a healthy start to the year overall [28][30] Question: How does the U.S. performance compare to expectations? - The U.S. performance in bracing was strong, while recon growth was in line with expectations, with room for improvement in the coming quarters [34][38] Question: What is the outlook for gross margins? - Management indicated that the strong gross margins are sustainable, driven by positive business mix and new product contributions [39][40] Question: What is the expectation for free cash flow and leverage by year-end? - The company expects to maintain positive free cash flow and leverage in the range of 3% to 3.5% by year-end [50][66] Question: How recession-proof is the business? - Management believes the business is resilient, with consistent long-term growth even during recessionary periods [71][72] Question: Will tariff dynamics affect margin expansion goals? - While there may be short-term impacts, management remains committed to long-term margin expansion goals [74][75]